Natco Pharma receives approval for generic Daclatasvir Dihydrochloride tablets in India

14 Dec 2015 Evaluate

Natco Pharma has received approval for generic Daclatasvir Dihydrochloride (‘Daclatasvir’) tablets, 30mg & 60mg, from Drugs Controller General (India). Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets. This is the first company in India to get approval for generic Daclatasvir Dihydrochloride.

The company will market generic Daclatasvir under its own brand NATDAC and through its strategic partners in India. The company will launch immediately in India at an MRP of Rs 6000 and Rs 4000 for the 60mg and 30mg strengths, respectively, for a bottle of 28 tablets. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


 

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×